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PBDE Flame Retardants and 
Thyroid Hormones during 
Pregnancy
doi:10.1289/ehp.1002782
Chevrier et al. (2010) assessed the association 
between 10 polybrominated diphenyl  ethers 
(PBDEs) and free and total thyroxine (T4) 
and thyroid-stimulating hormone (TSH) in 
270 women around the 27th week of gesta-
tion. They concluded that PBDEs are associ-
ated with lower TSH levels during pregnancy, 
but several factors that likely influenced the 
results were not considered in their analysis.
Normal pregnancy can lead to low TSH 
levels without affecting T4 levels, as can several 
other factors (e.g., starvation; stress; psychia  tric 
dis  orders; depression; acute or chronic non-
thyroidal disorders; alterations in thyrotropin- 
releasing hormone, cortisol, opio  dergic, dopa-
minergic, or somato  statinergic activity; and 
altera  tions in leptin and cytokine production) 
(Braverman and Utiger 2000; Krassas et al. 
2010). None of these were included in the 
analy  ses of Chevrier et al. (2010), yet any of 
them could have contributed to lower TSH 
levels. 
Chevrier et al. (2010) classified women 
in their second and third trimesters as having 
subclinical hyper  thyroidism if their serum 
TSH levels were < 0.5 mIU/L and < 0.8 
mIU/L, respectively. Krassas et al. (2010) 
recently reported TSH reference ranges: 5th 
percentiles for the second and third trimesters 
were 0.03–0.39 and 0.13 mIU/L, respectively, 
suggesting that the cutoffs used by Chevrier 
et al. (2010) led to an incorrect classification 
of at least some women. 
Chevrier et al. (2010) reported that blood 
was drawn at 27.3 ± 3.1 (mean ± SD) weeks 
gestation; however, it is unclear which women 
were in the second trimester and which were 
in the third trimester. Although Chevrier et al. 
(2010) adjusted for gestational age, the use 
of different cutoffs for a binary variable (sub-
clini  cal hyper  thyroidism) for women in the 
same analyses likely biased results, particularly 
considering that differences between women 
near the end of the second and beginning of 
the third trimester are not great. 
With the exception of a few outliers, the 
range of each PBDE among study subjects was 
quite small (all with the ratio of the 75th to 
the 25th percentile < 3.4). Because blood was 
drawn only once and all associations noted were 
quite weak, even a small difference between the 
measured PBDE level and the actual level in an 
individual could have biased the results.
All of the PBDE congeners were moder-
ately to strongly inter  correlated (r = 0.6–0.9; 
p < 0.001), yet analyses were conducted only 
by individual congener, leaving the inappro-
priate impression that several of the PBDE 
congeners may have been causally associated 
with lower TSH levels.
The limitations discussed above preclude 
one from drawing conclusions regarding asso-
ciations between serum PBDEs and TSH. It is 
notable, however, that even if associations are 
shown to be causal, the decrements in TSH 
reported are very small and mostly within the 
reference range for pregnant women. Thus, they 
are unlikely to result in adverse health effects in 
either pregnant women or their fetuses. 
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Goodman et al. raise concerns regarding our 
study (Chevrier et al. 2010) in which we 
reported associations between serum levels of 
polybrominated diphenyl ethers (PBDEs) and 
lower thyroid-stimulating hormone (TSH) in 
pregnant women participating in the Center 
for the Health Assessment of Mothers and 
Children of Salinas (CHAMACOS) cohort 
study. The points they raise are unlikely to 
have affected the validity of our conclusion.
Goodman et al. correctly point out that, 
as for most health outcomes, thyroid hor-
mone levels may be affected by a number 
of factors. However, these factors must be 
related to PBDE serum levels to confound 
the associations that we reported. Although 
it would be of interest to evaluate associa-
tions between exposure to PBDEs and the 
adverse health effects cited by Goodman et al. 
(e.g., psychiatric dis  orders, depression, neuro-
transmitter and hormonal alterations), we 
are aware of no study that investigated these 
relationships. Furthermore, should PBDEs 
cause these health effects, they would be on 
the causal pathway between exposure and dis-
ease, and as such, should not be adjusted for. 
Consequently, it is unlikely that the factors 
identified by Goodman et al. substantially 
confounded our results. On the other hand, 
we considered a large number of demo  graphic 
and environmental factors that may be related 
to both PBDE serum levels and thyroid func-
tion, and we observed little confounding 
(Chevrier et al. 2010). 
Goodman et al. also suggest that our 
results may be due to exposure and outcome 
mis  classi  fication based on a) the reference 
range that we used to determine sub  clinical 
hyper  thyroidism; b) our use of different cut-
offs for women in the second and third tri-
mesters of pregnancy; and c) the fact that we 
measured PBDEs at one time point during 
pregnancy. As explained below, we believe 
that substantial mis  classification is unlikely; 
even if misclassification did occur, it would 
most likely be nondifferential with regard to 
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exposure, which would be expected to bias 
associa  tions toward the null rather than create 
spurious relationships. 
Goodman et al. argue that in our study 
(Chevrier et al. 2010) we used inappropri-
ate reference ranges to determine sub  clinical 
hyper  thyroidism. Reference ranges for thy-
roid hormone are method, instrument, 
and gestational-age specific. The trimester-
specific reference ranges that we used were 
developed by Quest Diagnostics on a Bayer 
ADVIA Centaur system (Siemens Healthcare 
Diagnostics, Deerfield, IL), the instrument 
used for our analyses; thus, they were appro-
priate. Reference ranges cited by Goodman 
et al., however, were based on studies that 
used different methods and instruments   
and/or that were conducted earlier in preg-
nancy (e.g., ≤ 21 weeks of gestation) (Haddow 
et al. 2004; Price et al. 2001; Stricker et al. 
2007; as reviewed by Krassas et al. 2010). 
Goodman et al. criticize our use of differ-
ent reference ranges for women whose TSH 
was meas  ured in the second and third tri-
mesters of pregnancy. However, the National 
Academy of Clinical Biochemistry (Baloch 
et al. 2003), as well as authors cited by 
Goodman et al. (Krassas et al. 2010), recom-
mend using trimester-specific reference ranges 
because thyroid hormone levels change dur-
ing the course of pregnancy. Furthermore, we 
found inverse associations between PBDEs 
and TSH expressed continuously (Chevrier 
et al. 2010), demon  strating that the relation-
ships are not due to the cutoff points used to 
dichotomize TSH. 
Goodman et al. also believe that we should 
have taken multiple blood samples to deter-
mine exposure to PBDEs. The PBDE con-
geners that we measured, however, are highly 
persistent in humans (estimated half-lives of 
2–12 years). In addition, PBDE serum con-
centrations meas  ured at 27 weeks of gestation 
and at delivery were strongly correlated (r = 
0.82–0.99; p < 0.001) among CHAMACOS 
women, suggesting that a single measure  ment 
is suffi  cient to determine exposure. 
Goodman et al. state that the fact that 
congeners are inter  correlated leaves the impres-
sion that several congeners may be related 
to TSH. Correlation between the congeners 
was expected because they are components of 
the same commercial mixture (pentaBDE). 
Although identifying the specific congener(s) 
that may be related to thyroid hormone dis-
ruption is of scientific interest, it is of little 
relevance in terms of public health; relation-
ships between any one of the measured PBDE 
congeners and thyroid hormone levels is of 
concern. 
Finally, Pop et al. (1999) reported that 
small variations in maternal thyroid hor-
mone during pregnancy were related with 
altered child neuro  development. In our study 
(Chevrier et al. 2010), we reported a 37.7% 
reduction in TSH over the full range of total 
PBDEs and a 3.9-fold increase in the odds of 
subclinical hyper  thyroidism among women 
in the fourth quartile of BDE-100 relative to 
those in the first quartile. These associations 
are neither “very small” nor are they within the 
reference range, as argued by Goodman et al. 
PBDE serum concentrations in the 
CHAMACOS population (Chevrier et al. 
2010) were similar to those of the general 
U.S. population, and observed associations 
may be stronger in populations with higher 
exposure. Although, additional studies are 
needed to confirm our findings and to evalu-
ate the relation  ships between maternal sub-
clinical hyper  thyroidism and maternal and 
fetal health, we believe that our results merit 
consideration by policy makers as well as the 
bromine industry.
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Erratum
The November Science Selection article “Disinfection By-products and Bladder 
Cancer: Common Genetic Variants May Confer Increased Risk” [Environ Health 
Perspect 118:A491 (2010)] incorrectly stated that “Among individuals who carried 
both of the GSTT1 and GSTZ1 genotypes noted above (28% of study participants), 
those with the highest DBP exposure were at a 1.5 times increased risk of bladder 
cancer compared with carriers with the lowest DBP exposure.” Among individuals 
who carried both of the GSTT1 and GSTZ1 genotypes noted above (28% of study 
participants), those with the highest DBP exposure actually were at a 5.9 times 
increased risk of bladder cancer compared with carriers with the lowest DBP  
exposure. Risk was only 1.5 times higher with high versus low DBP exposure 
among study participants who lacked both genotypes. EHP regrets the error.